Welcome to the June homepage edition for i2P (Information to Pharmacists) E-Magazine.
The editor’s desk has been vacant for nearly a month to enable a short vacation to happen, and gratefully it has stirred some sort of a revival.
The volume of work unpublished over May will be reorganised and will appear gradually over future editions.
Since resuming “the desk” the pressure has recommenced, but that is part of the job.
This month we have featured Gerald Quigley as he illustrates an evidence-based complementary medicine that helps Alzheimer patients. The product is already helping patients but is being criticised because of a perceived lack of “quality” in its evidence profile.
Mark Coleman has jumped in to point out the lack of quality in mainstream evidence for drugs, and I find it quite appalling that a serial complainer can justify any mainstream evidence as being “gold standard”.
Read Mark’s article under the title of “Research and other Medical Wonders”.
Volume 1 Number 1
Volume 1 Number 2
Volume 1 Number 3
Volume 1 Number 4
Volume 1 Number 5
Volume 1 Number 6
Volume 1 Number 7
Volume 2 Number 1
Volume 2 Number 2
Volume 2 Number 3
Volume 2 Number 4
Volume 2 Number 5
Volume 2 Number 6
Volume 2 Number 7
Volume 2 Number 8
Volume 2 Number 9
Volume 2 Number 10
Volume 2 Number 11
Volume 3 Number 1
Volume 3 Number 2
Volume 3 Number 3
Volume 3 Number 4
Volume 3 Number 5
Volume 3 Number 6
Volume 3 Number 7
Volume 3 Number 8
Volume 3 Number 9
Volume 3 Number 10
Volume 3 Number 11
Volume 4 Number 1
Volume 4 Number 2
Volume 4 Number 3
Volume 4 Number 4
Volume 4 Number 5
Volume 4 Number 6
Volume 4 Number 7
Volume 4 Number 8
Volume 4 Number 9
Volume 4 Number 10
Volume 4 Number 11
Volume 5 Number 1
Volume 5 Number 2
Volume 5 Number 3
Volume 5 Number 4
Volume 5 Number 5
Editing and Researching news and stories about global and local Pharmacy Issues
Source: AAP NewsWire
Source: AAP NewsWire
The wind farm set to power Sydney's desalination plant will begin operation this week and its owner Infigen Energy says similar projects will drive the company's growth.
The 67-turbine Capital wind farm, near Bungendore, east of Canberra, will be opened on Wednesday.
It will be the largest wind farm in NSW and is more than five times the size of any other wind farm in the state, Infigen says.
The wind farm has a capacity of 140.7 megawatts (MW) and its total output could power about 60,000 homes, although average output is expected to be slightly more than one third of full capacity.
Under a 20-year contract signed last year, the majority of Capital wind farm's output will be used by Sydney Water to power its desalination plant at Kurnell, in the south suburbs of Sydney.
Infigen managing director Miles George said the desalination plant would use 40MW of electricity when it began operating this summer, and that any left over power generated by the wind farm would go into the national electricity grid.
The opening marks a major milestone for Infigen, formerly known as Babcock & Brown Wind Partners until a management internalisation in April this year.
With four operational Australian wind farms on its books, another under construction and a further 12 in its project pipeline, the company says the federal government's renewable energy targets will be the main driver for its future growth.
A major component would also be the supply of power to major infrastructure such as desalination plants, George said.
"We expect that desalination plants will be a significant part of our business, going forward," he told reporters.
"It's expected that there will be half a dozen or so still to come around the country.
"From our point of view, having large long-term customers who, like Sydney Water, are seeking to operate their plants in a carbon-neutral fashion ... we think is a great prospect for our business."
Plans to sell Infigen's wind farm assets in the United States, Germany and France are continuing on track, George said.
The company intends to use the proceeds to pay down debt and focus primarily on the Australian renewable energy sector.
Infigen said in August the sale process was expected to take six months and possibly longer in the US.
"We are well into that process now, and the processes are going very well, there's no change to our timetable," George said.
"We mentioned at the outset that there was very strong interest from all three jurisdictions for those assets and that remains the case."
The company would provide a trading update for the financial year-to-date at its annual general meeting next week, he said.Return to home